CL2015002837A1 - Compuestos de piridinilpirazoloquinolina. - Google Patents

Compuestos de piridinilpirazoloquinolina.

Info

Publication number
CL2015002837A1
CL2015002837A1 CL2015002837A CL2015002837A CL2015002837A1 CL 2015002837 A1 CL2015002837 A1 CL 2015002837A1 CL 2015002837 A CL2015002837 A CL 2015002837A CL 2015002837 A CL2015002837 A CL 2015002837A CL 2015002837 A1 CL2015002837 A1 CL 2015002837A1
Authority
CL
Chile
Prior art keywords
compounds
pyridinylpyrazoloquinoline
piridinylpirazoloquinoline
phosphodesterase
pde9
Prior art date
Application number
CL2015002837A
Other languages
English (en)
Inventor
Yoshihiko Norimine
Kunitoshi Takeda
Yuki Ishihara
Nobuaki Sato
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2015002837A1 publication Critical patent/CL2015002837A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPUESTOS DERIVADOS DE PIRIDINILPIRAZOLOQUINOLINA, INHIBIDORES DE LA FOSFODIESTERASA 9 (PDE9); COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; METODO PARA MEJORAR UNA DEFICIENCIA COGNITIVA EN LA ENFERMEDAD DE ALZHEIMER.
CL2015002837A 2013-04-05 2015-09-23 Compuestos de piridinilpirazoloquinolina. CL2015002837A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361809095P 2013-04-05 2013-04-05
US201361809118P 2013-04-05 2013-04-05

Publications (1)

Publication Number Publication Date
CL2015002837A1 true CL2015002837A1 (es) 2016-04-22

Family

ID=51658437

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002837A CL2015002837A1 (es) 2013-04-05 2015-09-23 Compuestos de piridinilpirazoloquinolina.

Country Status (20)

Country Link
US (1) US9550776B2 (es)
EP (1) EP2982674B1 (es)
JP (1) JP6244353B2 (es)
KR (1) KR102234131B1 (es)
CN (1) CN105189496B (es)
AU (1) AU2014250391B2 (es)
BR (1) BR112015024075B1 (es)
CA (1) CA2904820C (es)
CL (1) CL2015002837A1 (es)
ES (1) ES2654094T3 (es)
HK (1) HK1219100A1 (es)
IL (1) IL241695B (es)
MX (1) MX363258B (es)
PE (1) PE20151718A1 (es)
PH (1) PH12015502178A1 (es)
RU (1) RU2655172C2 (es)
SG (1) SG11201507733YA (es)
TW (1) TW201439091A (es)
WO (1) WO2014163146A1 (es)
ZA (1) ZA201507044B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406486D0 (en) 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
WO2017046606A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds
CA3061884A1 (en) 2017-06-01 2019-10-29 Eisai R&D Management Co., Ltd. Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
DK3682881T3 (da) 2017-09-14 2026-05-11 Daiichi Sankyo Co Limited Forbindelse med cyklisk struktur
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
AU2022306671A1 (en) 2021-07-07 2024-01-25 Incyte Corporation Tricyclic compounds as inhibitors of kras
JP2024529347A (ja) 2021-07-14 2024-08-06 インサイト・コーポレイション Ｋｒａｓの阻害剤としての三環式化合物
JP2024534187A (ja) 2021-08-31 2024-09-18 インサイト・コーポレイション Ｋｒａｓの阻害剤としてのナフチリジン化合物
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
EP4408536A1 (en) 2021-10-01 2024-08-07 Incyte Corporation Pyrazoloquinoline kras inhibitors
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
AU688515B2 (en) 1994-05-24 1998-03-12 F. Hoffmann-La Roche Ag Tricyclic dicarbonyl derivatives
DE102004004142A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
US20060035920A1 (en) 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
CN101268073B (zh) * 2005-09-15 2011-10-19 Aska制药株式会社 杂环化合物、制备方法及其用途
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
MX2009011830A (es) 2007-05-11 2009-11-13 Pfizer Compuestos amino-heterociclicos.
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
BRPI1009287A2 (pt) 2009-03-05 2019-09-24 Astellas Pharma Inc composto de quinoxalina
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
HRP20160473T1 (hr) 2010-09-07 2016-07-29 Astellas Pharma Inc. Pirazolokinolinski spojevi
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
ES2527188T3 (es) * 2011-09-26 2015-01-21 Sanofi Derivados de pirazolquinolinona, su preparación y su uso terapéutico
PL2769980T3 (pl) 2011-10-07 2016-07-29 Eisai R&D Man Co Ltd Pochodna pirazolochinoliny jako inhibitory PDE9

Also Published As

Publication number Publication date
CN105189496B (zh) 2017-03-29
CA2904820A1 (en) 2014-10-09
PE20151718A1 (es) 2015-11-22
ES2654094T3 (es) 2018-02-12
EP2982674A1 (en) 2016-02-10
BR112015024075A2 (pt) 2017-10-24
ZA201507044B (en) 2017-02-22
MX363258B (es) 2019-03-19
KR20150138204A (ko) 2015-12-09
CN105189496A (zh) 2015-12-23
KR102234131B1 (ko) 2021-04-01
AU2014250391A1 (en) 2015-10-15
US20160289225A1 (en) 2016-10-06
JP6244353B2 (ja) 2017-12-06
EP2982674A4 (en) 2016-08-31
SG11201507733YA (en) 2015-10-29
RU2655172C2 (ru) 2018-05-24
RU2015140669A (ru) 2017-05-11
TW201439091A (zh) 2014-10-16
HK1219100A1 (en) 2017-03-24
IL241695B (en) 2019-06-30
US9550776B2 (en) 2017-01-24
EP2982674B1 (en) 2017-10-25
PH12015502178A1 (en) 2016-01-25
CA2904820C (en) 2021-05-18
JPWO2014163146A1 (ja) 2017-02-16
WO2014163146A1 (ja) 2014-10-09
MX2015013446A (es) 2016-01-12
AU2014250391B2 (en) 2017-11-02
RU2015140669A3 (es) 2018-03-21
BR112015024075B1 (pt) 2022-05-03

Similar Documents

Publication Publication Date Title
UY34559A (es) Inhibidores de bromodominios
UY34765A (es) Compuestos novedosos.
BR112015032718A2 (pt) composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
CL2016001063A1 (es) Locus optimos de la soja.
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA201591137A1 (ru) Ингибиторы mk2 и их применения
DK2970283T3 (da) Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34697A (es) Métodos para preparar análogos de nucleótidos
LT3323814T (lt) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oksazepan-2-karboksamidai kaip dipeptidil peptidazės 1 inhibitoriai
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
UY4235Q (es) Configuración aplicada en zapato
UY34515A (es) Triazolopiridinas sustituidas
UY34156A (es) Compuestos inhibidores de metaloenzimas
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
LT3386991T (lt) Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
MX2018001793A (es) Compuestos para dispositivos opticamente activos.
EA201600121A1 (ru) Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
UY34329A (es) Compuestos de triazolopiridina
CL2015002358A1 (es) Compuestos bicíclicos.
UY34791A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida